SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
95 hedge funds and large institutions have $1.92B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 10 closing their positions.
1,848% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $557K
76% more capital invested
Capital invested by funds: $1.09B → $1.92B (+$825M)
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
7% more funds holding
Funds holding: 89 → 95 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$51.7M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$36.4M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$32.5M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$23.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$8.81M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$8.25M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$8.16M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.07M |
| 5 |
Millennium Management
New York
|
-$5.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Jane Street
New York
| – | -$417K | -9,940 | Closed |
|
|
NCCM
102
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$269K | -6,400 | Closed |
|
103
Renaissance Technologies
New York
| – | -$239K | -5,701 | Closed |
|
|
TC
104
Travelers Companies
Saint Paul,
Minnesota
| – | -$82K | -1,965 | Closed |
|
|
BAM
105
Barrett Asset Management
New York
| – | -$3K | -79 | Closed |
|
GEVA Hedge Fund Activity: Q3 2013 in Review
95 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q3 2013, worth a combined $1.92B — up 76% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GEVA positions and 10 closed out — a net gain of 7 holders — while 43 added to existing stakes and 28 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $51.7M. The largest seller was Turner Investments, exiting entirely with an estimated $8.81M sold.
- 95 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q3 2013, up from 89 in Q2 2013.
- Funds reported $1.92B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q3 2013, up 76% quarter-over-quarter.
- 17 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q3 2013 and 10 closed out, a net change of +7 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q3 2013 was Baker Bros. Advisors, an estimated $51.7M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q3 2013 was Turner Investments, an estimated $8.81M sold.
Based on aggregated 13F filings for Q3 2013.